BioSpace News Archive

Pharnext Announces a New Financing Through a Convertible Bond Program for a Total Amount up to €81 Million Gross to Extend its Cash Runway and to Continue to Fund its Pivotal Phase III Study of PXT3003, the PREMIER trial, in Charcot-Marie-Tooth Disease Type 1A

MammaPrint was the only test to predict significant 36% and 52% reductions in DFS and BCFI events, respectively, for patients treated with extended endocrine therapy

Pre-clinical Data Support Plans to Advance CFT8919 to Clinical Development with IND Submission Expected in mid-2022 and Clinical Trial Initiation Expected by YE 2022

Cerecor Inc., a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, announced that it has entered into a debt financing agreement led by Horizon Technology Finance Corporation to provide up to $35.0 million in term loans.

Data demonstrate that combination of plinabulin and pegfilgrastim offers superior benefit for reducing the incidence and severity of febrile neutropenia (FN) and hospitalization, with better quality-of-life (QoL), compared to pegfilgrastim alone

Single-dose administration of IN8bio’s genetically modified gamma delta T-cells in lymphodepleted glioblastoma multiforme (GBM) patients was well tolerated

Celltrion Healthcare Canada Limited announced the launch of Remsima™ SC, the world’s first subcutaneous formulation of infliximab in Canada for the treatment of adult patients with rheumatoid arthritis.

Gamida Cell Ltd., an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced the appointment of Vladimir Melnikov as senior vice president, global operations and manufacturing.

New examination of AURORA 1 Phase 3 data demonstrates increased renal response rates with LUPKYNIS™ (voclosporin) used in combination with MMF and low-dose steroids in patients with lupus nephritis regardless of target urine protein creatinine ratio (UPCR)

OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced that it has submitted an updated 510 summary document to the U.S. FDA for its Acuitas AMR Gene Panel for Isolates.